SCHEMBL3016483

SCHEMBL3016483

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4c(C)cc(C)cc4C)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
DNM1L O00429 12/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
GBA1 P04062 1/20 0.35
AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011125 0.94 DNM1L (0.35) SMN1; SMN2NPC1RAB9ADNM1LKMT2A
SCHEMBL3007167 0.93 EPHX2 (0.39) SMN1; SMN2DNM1LKMT2AMAPTNPSR1
SCHEMBL3008362 0.93 DNM1L (0.42) DNM1LKMT2AMEN1GBA1
SCHEMBL3000967 0.92 FFAR4 (0.35) DNM1LKMT2AMEN1
SCHEMBL3016255 0.92 DNM1L (0.35) SMN1; SMN2NPC1RAB9ADNM1LKMT2A
SCHEMBL3002261 0.92 DNM1L (0.38) SMN1; SMN2NPC1RAB9ADNM1LKMT2A
SCHEMBL3006118 0.91 RAB9A (0.40) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL3015170 0.91 SMN1; SMN2 (0.38) SMN1; SMN2NPC1RAB9ADNM1LKMT2A
SCHEMBL3010776 0.90 MAPT (0.37) SMN1; SMN2NPC1RAB9AKMT2APOLB
SCHEMBL3007844 0.89 CACNA1G (0.36) SMN1; SMN2NPC1RAB9ADNM1LKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.